SCHEMBL5014342

SCHEMBL5014342

NOCc1cccc(-c2cccnc2)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 6/20 0.53
HSP90AA1 P07900 1/20 0.47
HSP90AB1 P08238 1/20 0.47
PTK2 Q05397 1/20 0.47
CYP19A1 P11511 2/20 0.42
ALDH1A1 P00352 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
PDE10A Q9Y233 1/20 0.41
NPC1 O15118 1/20 0.41
LOXL2 Q9Y4K0 1/20 0.41
AXL P30530 2/20 0.41
MKNK1 Q9BUB5 2/20 0.41
MKNK2 Q9HBH9 2/20 0.41
PBRM1 Q86U86 1/20 0.41
CYP2C9 P11712 2/20 0.40
CYP2B6 P20813 2/20 0.40
CYP2C19 P33261 2/20 0.40
ABL1 P00519 2/20 0.40
EGFR P00533 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5014400 0.84 ABL1 (0.34) CYP2A6ALDH1A1PDE10AABL1MEN1
SCHEMBL27362244 0.82 CYP2A6 (0.54) CYP2A6HSP90AA1HSP90AB1PTK2CYP19A1
SCHEMBL14075026 0.81 CYP2A6 (0.49) CYP2A6HSP90AA1HSP90AB1PTK2CYP19A1
SCHEMBL24701007 0.79 CYP2A6 (0.57) CYP2A6HSP90AA1HSP90AB1PTK2CYP19A1
SCHEMBL2759492 0.79 CYP2A6 (0.62) CYP2A6HSP90AA1HSP90AB1PTK2CYP19A1
SCHEMBL5012722 0.78 GABRA1 (0.39) CYP2A6HSP90AA1CYP19A1ALDH1A1CYP2C9
SCHEMBL3194702 0.77 CYP2A6 (0.74) CYP2A6HSP90AA1HSP90AB1PTK2CYP19A1
SCHEMBL5012773 0.77 MAP4K4 (0.41) ALDH1A1NPC1MKNK1MKNK2MEN1
SCHEMBL5014483 0.76 MEN1 (0.46) ALDH1A1NPC1AXLMKNK1MKNK2
SCHEMBL5014375 0.76 MAPT (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7419962-B2 3,6-bicyclolides ENANTA PHARMACEUTICALS, INC. (US) 2008-09-02 US disclosed
EP-1830858-A2 3, 6-BICYCLOLIDES Enanta Pharmaceuticals, Inc. (US) 2007-09-12 EP disclosed
US-20060142214-A1 3,6-bicyclolides ENANTA PHARMACEUTICALS, INC. 2006-06-29 US disclosed
WO-2006063039-A2 3, 6-BICYCLOLIDES ENANTA PHARMACEUTICALS, INC. (US) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142214-A1 3,6-bicyclolides ABCB11, CYP2B6, CYP3A7 CYP2A6 12/4885HSP90AA1 2811/4885HSP90AB1 2052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.